You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Claims for Patent: 10,905,694


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,905,694
Title:Pharmaceutical solid preparation comprising benzazepines and production method thereof
Abstract: The subject invention provides a novel pharmaceutical solid preparation that has superior disintegration properties and excellent solubility, leading to sufficient absorbability of active ingredients through the gastrointestinal tract. The pharmaceutical solid preparation of the present invention comprises: (a) 7-chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-t- etrahydro-1H-benzoazepine and/or salt thereof; (b) hydroxypropylcellulose containing a hydroxypropoxyl group in an amount of 50% or greater; and (c) at least one member selected from the group consisting of carmellose, sodium carboxy methyl starch, crospovidone, and low substituted hydroxypropylcellulose with an average particle diameter of 30 to 70 .mu.m, and a 90% cumulative particle diameter of 100 to 200 .mu.m.
Inventor(s): Nakagawa; Shinsuke (Osaka, JP), Suzuki; Kai (Osaka, JP), Mukai; Tadashi (Osaka, JP)
Assignee: OTSUKA PHARMACEUTICAL CO., LTD. (Tokyo, JP)
Application Number:12/665,642
Patent Claims: 1. A pharmaceutical solid preparation obtained by a method, comprising: Step 1 of producing amorphous composites consisting of (a) 7-chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-t- etrahydro-1H-benzoazepine and/or salt thereof, and (b) hydroxypropylcellulose containing a hydroxypropoxyl group in an amount of 50% or greater; Step A of processing a mixture of (i) the amorphous composites obtained in Step 1, (ii) crystalline cellulose, and (iii) corn starch and/or lactose into granules using a granulation method; Step 2 of mixing the granules obtained in Step A with (c-1) low substituted hydroxypropylcellulose, to obtain a mixture, wherein the low substituted hydroxypropylcellulose is cellulose containing a hydroxy propoxyl group in an amount of about 10 to 13%, has an average particle diameter of 45 to 65 .mu.m, and has a 90% cumulative particle diameter of 150 to 200 .mu.m, and the component (c-1) directly contacts at least some of the amorphous composites; and Step 3 of processing the mixture obtained in Step 2 into a solid preparation, wherein the content of the component (c-1) is 1 to 15 wt % of the solid preparation.

2. The pharmaceutical solid preparation according to claim 1, wherein the pharmaceutical solid preparation is a form of tablet.

3. The pharmaceutical solid preparation according to claim 2, wherein Step 3 includes coating the tablet with an enteric film or a sustained-release film to modify a drug release in the gastrointestinal tract.

4. The pharmaceutical solid preparation according to claim 1, wherein the content of (a) the 7-chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-t- etrahydro-1H-benzoazepine and/or salt thereof is 0.01 to 95 wt % of the solid preparation.

5. The pharmaceutical solid preparation according to claim 1, wherein the content of (b) the hydroxypropylcellulose containing the hydroxypropoxyl group in the amount of 50% or greater is 0.01 to 2 times that of the content of (a) the 7-chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-t- etrahydro-1H-benzoazepine and/or salt thereof in the solid preparation.

6. The pharmaceutical solid preparation according to claim 1, wherein the content of the component (c-1) is 3 to 12 wt % of the solid preparation.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.